Orchestra BioMed Reports Long-Term, Reversible Blood Pressure Benefits Of AVIM Therapy; Results Support Durable, Programmable Treatment For Uncontrolled Hypertension

Author: Benzinga Newsdesk | September 04, 2025 05:01pm

• Results from long-term follow up of patients treated with atrioventricular interval modulation ("AVIM") therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed rebound hypertension upon deactivation of treatment, and reproducible upon reactivation following a washout period
• Simultaneous peer-reviewed publication of AVIM therapy mechanistic and clinical results
• Orchestra BioMed and Medtronic (NYSE:MDT) have a strategic collaboration to develop and commercialize AVIM therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annually
• AVIM therapy has FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, an estimated U.S. population of over 7.7 million patients

NEW HOPE, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced new data from its AVIM therapy program, presented at the HRX Live 2025 Meeting, in Atlanta, GA, demonstrating that the blood pressure-lowering effects of AVIM therapy may be sustained for years after activation, are reversible with no evidence of rebound hypertension or blood pressure exceeding initial baseline values, and can be restored upon reactivation. These data further support AVIM therapy's potential role as a controllable, programmable, and durable device-based therapy for uncontrolled hypertension.

Posted In: OBIO